UB Paderborn / Katalog / Suche / in CDI

1 – 25 von 56

Sortiert nach

The Depsipeptide Romidepsin Reverses HIV-1 Latency In Vivo

PLoS pathogens, 2015-09, Vol.11 (9), p.e1005142-e1005142

2015

Volltextzugriff (PDF)

A novel peptide-based vaccine candidate with protective efficacy against influenza A in a mouse model

Virology (New York, N.Y.), 2018-02, Vol.515, p.21-28

2018

Volltextzugriff (PDF)

Re-boost immunizations with the peptide-based therapeutic HIV vaccine, Vacc-4x, restores geometric mean viral load set-point during treatment interruption

PloS one, 2019-01, Vol.14 (1), p.e0210965-e0210965

2019

Volltextzugriff (PDF)

A case for preART-adjusted endpoints in HIV therapeutic vaccine trials

Vaccine, 2016-03, Vol.34 (10), p.1282-1288

2016

Volltextzugriff (PDF)

Intranasal administration of a therapeutic HIV vaccine (Vacc-4x) induces dose-dependent systemic and mucosal immune responses in a randomized controlled trial

PloS one, 2014-11, Vol.9 (11), p.e112556-e112556

2014

Volltextzugriff (PDF)

T-cell-mediated and humoral approaches to universal influenza vaccines

Expert review of vaccines, 2011-10, Vol.10 (10), p.1359-1361

Sommerfelt, Maja A

2011

Volltextzugriff (PDF)

Correlation of Antibody Responses to a Peptide Antigen gp120-C5 501-512 /gp41 732-744 with HIV Disease Progression

AIDS research and human retroviruses, 2017-06, Vol.33 (6), p.558

2017

Volltextzugriff (PDF)

Cell-Mediated Immune Predictors of Vaccine Effect on Viral Load and CD4 Count in a Phase 2 Therapeutic HIV-1 Vaccine Clinical Trial

EBioMedicine, 2017-10, Vol.24 (C), p.195-204

2017

Volltextzugriff (PDF)

Combinations in the first-line treatment of patients with advanced/metastatic renal cell cancer: regulatory aspects

ESMO open, 2020-08, Vol.5 (4), p.e000856, Article e000856

2020

Volltextzugriff (PDF)

Circular CCR5 peptide conjugates and uses thereof (WO2008074895)

Expert opinion on therapeutic patents, 2009-09, Vol.19 (9), p.1323-1328

Sommerfelt, Maja A

2009

Volltextzugriff (PDF)

European Medicines Agency extension of indication to include the combination immunotherapy cancer drug treatment with nivolumab (Opdivo) and ipilimumab (Yervoy) for adults with intermediate/poor-risk advanced renal cell carcinoma

ESMO open, 2020-01, Vol.5 (6), p.e000798-e000798, Article e000798

2020

Volltextzugriff (PDF)

Retrovirus receptors

Journal of general virology, 1999-12, Vol.80 ( Pt 12) (12), p.3049-3064

Sommerfelt, Maja A

1999

Volltextzugriff (PDF)

Low frequency of amino acid alterations following therapeutic immunization with HIV-1 Gag p24-like peptides

AIDS (London), 2010-11, Vol.24 (17), p.2609-2618

2010

Volltextzugriff (PDF)

Prospects for HIV-1 therapeutic immunisation and vaccination: the potential contribution of peptide immunogens

Expert opinion on biological therapy, 2008-06, Vol.8 (6), p.745-757

2008

Volltextzugriff (PDF)

Effect of the Modification of p24 Peptide Antigen on Dendritic Cell Uptake and T Cell Activation

Current HIV research, 2017-01, Vol.15 (1), p.3

2017

Volltextzugriff (PDF)

Delayed-type hypersensitivity responses to HIV Gag p24 relate to clinical outcome after peptide-based therapeutic immunization for chronic HIV infection

APMIS : acta pathologica, microbiologica et immunologica Scandinavica, 2012-03, Vol.120 (3), p.204-209

2012

Volltextzugriff (PDF)

Safety and efficacy of the peptide-based therapeutic vaccine for HIV-1, Vacc-4×: a phase 2 randomised, double-blind, placebo-controlled trial

The Lancet infectious diseases, 2014-04, Vol.14 (4), p.291-300

2014

Volltextzugriff (PDF)

HLA- and dose-dependent immunogenicity of a peptide-based HIV-1 immunotherapy candidate (Vacc-4x)

AIDS (London), 2004-09, Vol.18 (14), p.1875-1883

2004

Volltextzugriff (PDF)

Long-term HIV-specific responses and delayed resumption of antiretroviral therapy after peptide immunization targeting dendritic cells

AIDS (London), 2006-02, Vol.20 (4), p.627-630

2006

Volltextzugriff (PDF)

Reduced viral burden amongst high responder patients following HIV-1 p24 peptide-based therapeutic immunization

Vaccine, 2005-07, Vol.23 (31), p.4011-4015

2005

Volltextzugriff (PDF)

Multiple antigen concentrations in delayed-type hypersensitivity (DTH) and response diversity during and after immunization with a peptide-based HIV-1 immunotherapy candidate (Vacc-4x)

Vaccine, 2006-03, Vol.24 (10), p.1543-1550

2006

Volltextzugriff (PDF)

The endogenous langur type D retrovirus PO-1-Lu and its exogenous counterparts in macaque and langur monkeys

Virology (New York, N.Y.), 2003-10, Vol.315 (2), p.275-282

2003

Volltextzugriff (PDF)

Divergent in vitro and in vivo correlates of HIV-specific T-cell responses during onset of HIV viraemia

AIDS (London), 2005-03, Vol.19 (6), p.563-567

2005

Volltextzugriff (PDF)

1 – 25 von 56

Suche als RSS-Feed

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(51)
Mit Volltextzugriff
(50)

Publikationsform

Artikel
(52)
Buchkapitel
(4)

Sprache

Englisch
(56)
Japanisch
(2)

Erscheinungsjahr

n.n

Thema

Science & Technology
(42)
Humans
(40)
Life Sciences & Biomedicine
(38)
Virology
(27)
Biological And Medical Sciences
(21)
Animals
(17)
Infectious Diseases
(17)
Hiv
(16)
Immunology
(16)
Microbiology
(16)
Aids/hiv
(15)
Fundamental And Applied Biological Sciences. Psychology
(15)
Hiv Infections - Immunology
(14)
Human Immunodeficiency Virus
(13)
Aids Vaccines - Administration & Dosage
(11)
Aids Vaccines - Immunology
(11)
Human Immunodeficiency Virus 1
(11)
Cell Line
(10)
Female
(10)
Hiv-1 - Immunology
(10)

15 weitere anzeigen...

Weniger anzeigen...

Zeitschrift / Serie

5 weitere anzeigen...

Weniger anzeigen...

Menü

Weitere Dienste

Einstellungen

The Depsipeptide Romidepsin Reverses HIV-1 Latency In Vivo

Combined effect of Vacc-4x, recombinant human granulocyte macrophage colony-stimulating factor vaccination, and romidepsin on the HIV-1 reservoir (REDUC): a single-arm, phase 1B/2A trial

A novel peptide-based vaccine candidate with protective efficacy against influenza A in a mouse model

Re-boost immunizations with the peptide-based therapeutic HIV vaccine, Vacc-4x, restores geometric mean viral load set-point during treatment interruption

Safety and efficacy of the peptide-based therapeutic vaccine for HIV-1, Vacc-4x: a phase 2 randomised, double-blind, placebo-controlled trial

A case for preART-adjusted endpoints in HIV therapeutic vaccine trials

Intranasal administration of a therapeutic HIV vaccine (Vacc-4x) induces dose-dependent systemic and mucosal immune responses in a randomized controlled trial

T-cell-mediated and humoral approaches to universal influenza vaccines

Correlation of Antibody Responses to a Peptide Antigen gp120-C5 501-512 /gp41 732-744 with HIV Disease Progression

Cell-Mediated Immune Predictors of Vaccine Effect on Viral Load and CD4 Count in a Phase 2 Therapeutic HIV-1 Vaccine Clinical Trial

Combinations in the first-line treatment of patients with advanced/metastatic renal cell cancer: regulatory aspects

Circular CCR5 peptide conjugates and uses thereof (WO2008074895)

European Medicines Agency extension of indication to include the combination immunotherapy cancer drug treatment with nivolumab (Opdivo) and ipilimumab (Yervoy) for adults with intermediate/poor-risk advanced renal cell carcinoma

Retrovirus receptors

Low frequency of amino acid alterations following therapeutic immunization with HIV-1 Gag p24-like peptides

Prospects for HIV-1 therapeutic immunisation and vaccination: the potential contribution of peptide immunogens

Effect of the Modification of p24 Peptide Antigen on Dendritic Cell Uptake and T Cell Activation

Delayed-type hypersensitivity responses to HIV Gag p24 relate to clinical outcome after peptide-based therapeutic immunization for chronic HIV infection

Safety and efficacy of the peptide-based therapeutic vaccine for HIV-1, Vacc-4×: a phase 2 randomised, double-blind, placebo-controlled trial

HLA- and dose-dependent immunogenicity of a peptide-based HIV-1 immunotherapy candidate (Vacc-4x)

Long-term HIV-specific responses and delayed resumption of antiretroviral therapy after peptide immunization targeting dendritic cells

Reduced viral burden amongst high responder patients following HIV-1 p24 peptide-based therapeutic immunization

Multiple antigen concentrations in delayed-type hypersensitivity (DTH) and response diversity during and after immunization with a peptide-based HIV-1 immunotherapy candidate (Vacc-4x)

The endogenous langur type D retrovirus PO-1-Lu and its exogenous counterparts in macaque and langur monkeys

Divergent in vitro and in vivo correlates of HIV-specific T-cell responses during onset of HIV viraemia

Suchergebnisse filtern